Jiangsu Hengrui Medicine Co., Ltd

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

A Phase I Study of Famitinib Malate in Patients With Solid Tumor

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: Famitinib Malate Capsule

First Posted Date: 2013-01-07

Last Posted Date: 2018-04-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 55

Registration Number: NCT01762280

Locations: 🇨🇳
Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Colorectal Cancer Recurrent
Colorectal Cancer Metastatic

Interventions: Other: placebo
Drug: Famitinib

First Posted Date: 2013-01-07

Last Posted Date: 2018-04-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 154

Registration Number: NCT01762293

Locations: 🇨🇳
Cancer center, Sun Yet-sen University, Guangzhou, Guangdong, China
🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, China

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Phase 3

Completed

Conditions: Breast Cancer
Neutropenia
Febrile Neutropenia

Interventions: Drug: rhG-CSF 5ug/kg/day

First Posted Date: 2012-06-04

Last Posted Date: 2013-01-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 330

Registration Number: NCT01611051

Locations: 🇨🇳
Hospital Affiliated to Academy Military Medical Science, Beijing, Beijing, China

A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy

Phase 3

Conditions: NSCLC
Neutropenia
Febrile Neutropenia

Interventions: Drug: placebo and rhG-CSF 5ug/kg/d

First Posted Date: 2012-03-22

Last Posted Date: 2012-11-06

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT01560195

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: apatinib

First Posted Date: 2012-02-13

Last Posted Date: 2015-04-03

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT01531777

Locations: 🇨🇳
Fudan University cancer hospital, Shanghai, Shanghai, China

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Phase 3

Completed

Conditions: Advanced or Metastatic Gastric Cancer

Interventions: Drug: placebo
Drug: apatinib

First Posted Date: 2012-01-19

Last Posted Date: 2016-10-17

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 267

Registration Number: NCT01512745

Locations: 🇨🇳
The 81 Hosiptal of PLA, Nanjing, Jiangsu, China
🇨🇳
Fudan University cancer hospital, Shanghai, Shanghai, China

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Phase 2

Conditions: Non-hypovolemic Non-acute Hyponatremia

Interventions: Drug: Placebo
Drug: Tolvaptan

First Posted Date: 2012-01-11

Last Posted Date: 2012-01-11

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT01507727

Locations: 🇨🇳
Cardiology, Beijing An Zhen Hospital Affiliated to Capital University of Medical Science, Beijing, China
🇨🇳
Hepatology, No. 302 Hospital, Beijing, China
🇨🇳
Endocrinology, Beijing Friendship Hospital, Beijing, China

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Phase 2

Conditions: Myelogenous Leukemia, Chronic

Interventions: Drug: flumatinib
Drug: imatinib

First Posted Date: 2012-01-04

Last Posted Date: 2013-04-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT01503502

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
The First Rffiurted Hospital of Soochow University, Suzhou, Jiangsu, China

and more 2 locations

Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma

Phase 1

Completed

Conditions: Locally Advanced Nasopharyngeal Carcinoma

Interventions: Drug: Famitinib
Drug: Cisplatin
Radiation: radiation（IMRT）

First Posted Date: 2011-10-31

Last Posted Date: 2018-04-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT01462474

Locations: 🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

Phase 1

Terminated

Conditions: Advanced Solid Cancer

Interventions: Drug: henatinib

First Posted Date: 2011-08-15

Last Posted Date: 2012-12-21

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT01416623

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy